Investigational Drug Information for ASP2151
✉ Email this page to a colleague
What is the drug development status for ASP2151?
ASP2151 is an investigational drug.
There have been 13 clinical trials for ASP2151.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2013.
The most common disease conditions in clinical trials are Herpes Zoster, Herpes Simplex, and Herpes Genitalis. The leading clinical trial sponsors are Maruho Europe Limited, Astellas Pharma Inc, and Maruho Co., Ltd.
There are three US patents protecting this investigational drug and sixty-five international patents.
Summary for ASP2151
| US Patents | 3 |
| International Patents | 65 |
| US Patent Applications | 31 |
| WIPO Patent Applications | 26 |
| Japanese Patent Applications | 15 |
| Clinical Trial Progress | Phase 3 (2013-11-01) |
| Vendors | 40 |
Recent Clinical Trials for ASP2151
| Title | Sponsor | Phase |
|---|---|---|
| Drug-Drug Interaction Study: ASP2151 and Midazolam | Maruho Europe Limited | Phase 1 |
| Drug-Drug Interaction Study: ASP2151 and Bupropion | Maruho Europe Limited | Phase 1 |
| Drug-Drug Interaction Study: ASP2151 and Montelukast | Maruho Europe Limited | Phase 1 |
Clinical Trial Summary for ASP2151
Top disease conditions for ASP2151
Top clinical trial sponsors for ASP2151
US Patents for ASP2151
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ASP2151 | ⤷ Try a Trial | Viral prophylaxis treatment methods and pre-exposure prophylaxis kits | ELIAN LLC (Monrovia, CA) | ⤷ Try a Trial |
| ASP2151 | ⤷ Try a Trial | Crystalline form of 5-amino-2,3-dihydrophthalazine-1,4-dione sodium salt, pharmaceutical preparations containing the same and method for the production of said form | Metriopharm AG (Zurich, CH) | ⤷ Try a Trial |
| ASP2151 | ⤷ Try a Trial | Agents for the treatment of retroviral infectious diseases | IMMUNOLOGIK GMBH (Trockenborn-Wolfersdorf, DE) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ASP2151
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ASP2151 | Australia | AU2015287994 | 2034-07-07 | ⤷ Try a Trial |
| ASP2151 | Australia | AU2020203896 | 2034-07-07 | ⤷ Try a Trial |
| ASP2151 | Australia | AU2022275517 | 2034-07-07 | ⤷ Try a Trial |
| ASP2151 | Brazil | BR112017000285 | 2034-07-07 | ⤷ Try a Trial |
| ASP2151 | Canada | CA2954526 | 2034-07-07 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
